Arecor Therapeutics plc (AREC.L)
| Previous close | 136.50 |
| Open | 133.00 |
| Bid | 133.00 x N/A |
| Ask | 140.00 x N/A |
| Day's range | 133.00 - 137.50 |
| 52-week range | 125.00 - 280.00 |
| Volume | |
| Avg. volume | 14,475 |
| Market cap | 41.806M |
| Beta (5Y monthly) | -0.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.31 |
| Earnings date | 22 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 471.00 |
GlobeNewswireARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY
Arecor Therapeutics plc(“Arecor” or the “Company”) ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY Companies to combine proprietary technologies to formulate an oral semaglutide (GLP-1 receptor agonist) product with enhanced bioavailability Collaboration focused on overcoming the challenges of oral peptide delivery using a novel lipid technology to provide a more convenient treatment option for patients with diabetes and obesityPote
Simply Wall St.Will Arecor Therapeutics (LON:AREC) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe
Arecor Therapeutics plc(“Arecor” or the “Group”) FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE First commercial sale triggers milestone payment and future royalties to Arecor Cambridge, UK, 17 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a prod
